The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

Peking University

Status: Not yet enrolling

Conditions: CLL

Treatments: Drug: BTK inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT06557304

BTKi-CLL-RWE

Details and patient eligibility

About

This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Patients aged ≥18 years old
2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
4. Prior or current use of BTK inhibitor for ≥3 months
5. At least one follow-up was recorded during BTK inhibitor treatment